The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers

Molecular Carcinogenesis

Volumn 54, Issue 10, 2015, Pages 1172-1180

  Bae, Woo Kyun ^a,b   Yoo, Kyung Hyun ^a   Lee, Ji Shin ^b   Kim, Young ^b   Chung, Ik Joo ^b   Park, Min Ho ^b   Yoon, Jung Han ^b   Furth, Priscilla A ^c   Hennighausen, Lothar ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Chonnam National University Medical School   (South Korea)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cancer; EZH2; Histone modification; Prognosis; UTX

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H3; HISTONE H3 LYSINE 27; METHYLTRANSFERASE; PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UTX PROTEIN; ESTROGEN RECEPTOR; EZH2 PROTEIN, HUMAN; HISTONE DEMETHYLASE; KDM6B PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE CONTROL; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TUMOR VOLUME; ANIMAL; BREAST; BREAST TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BRCA1 PROTEIN; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; METHYLTRANSFERASES; MICE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RECEPTORS, ESTROGEN; YOUNG ADULT;

EID: 84941735991     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22188     Document Type: Article

References (41)

1. Ko SS. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: Biannual update. J Surg Oncol 2008; 98:318-323.
2. Khan SN, Jankowska AM, Mahfouz R, et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 2013; 27:1301-1309.
3. Piunti A, Pasini D. Epigenetic factors in cancer development: Polycomb group proteins. Future Oncol 2011; 7:57-75.
4. Laible G, Wolf A, Dorn R, et al. Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 1997; 16:3219-3232.
5. Sauvageau M, Sauvageau G. Polycomb group proteins: Multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7:299-313.
6. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100:11606-11611.
7. Gonzalez ME, Moore HM, Li X, et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci USA 2014; 111:3098-3103.
8. Granit RZ, Gabai Y, Hadar T, et al. EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene 2013; 32:3886-3895.
9. Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012; 26:651-656.
10. Muto T, Sashida G, Oshima M, et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013; 210:2627-2639.
11. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117:2451-2459.
12. Holm K, Grabau D, Lovgren K, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 2012; 6:494-506.
13. Lee MG, Villa R, Trojer P, et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 2007; 318:447-450.
14. Issaeva I, Zonis Y, Rozovskaia T, et al. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol Cell Biol 2007; 27:1889-1903.
15. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705.
16. van Haaften G, Dalgliesh GL, Davies H, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41:521-523.
17. Elsheikh SE, Green AR, Rakha EA, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009; 69:3802-3809.
18. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999; 22:37-43.
19. Pharoah PD, Caldas C. Genetics: How to validate a breast cancer prognostic signature. Nat Rev Clin Oncol 2010; 7:615-616.
20. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8:R76.
21. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008; 47:701-706.
22. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23:732-740.
23. Kok M, Linn SC, Van Laar RK, et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2009; 113:275-283.
24. Jansen MP, Reijm EA, Sieuwerts AM, et al. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat 2012; 133:937-947.
25. Reijm EA, Jansen MP, Ruigrok-Ritstier K, et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat 2011; 125:387-394.
26. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 2006; 66:4095-4099.
27. Li X, Gonzalez ME, Toy K, Filzen T, Merajver SD, Kleer CG. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol 2009; 175:1246-1254.
28. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-726.
29. Shiogama S, Yoshiba S, Soga D, Motohashi H, Shintani S. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration. Anticancer Res 2013; 33:4309-4317.
30. van Vlerken LE, Kiefer CM, Morehouse C, et al. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med 2013; 2:43-52.
31. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226-231.
32. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22:425-437.
33. Chan KM, Fang D, Gan H, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 2013; 27:985-990.
34. Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340:857-861.
35. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88:141-150.
36. Ellinger J, Kahl P, von der Gathen J, et al. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. Cancer Invest 2012; 30:92-97.
37. Tzao C, Tung HJ, Jin JS, et al. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 2009; 22:252-260.
38. Cai MY, Tong ZT, Zhu W, et al. H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol Med 2011; 17:1137-1145.
39. Cai MY, Hou JH, Rao HL, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 2011; 17:12-20.
40. Wang JK, Tsai MC, Poulin G, et al. The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev 2010; 24:327-332.
41. Wang L, Zeng X, Chen S, et al. BRCA1 is a negative modulator of the PRC2 complex. EMBO J 2013; 32:1584-1597.